#USA #AI Imaging #Charlottesville #RIVANNA #Accuro XV

RIVANNA's Expansion of Accuro XV Multi-Site Clinical Study

RIVANNA®, a pioneering company in AI-driven clinical decision support solutions, is making significant strides in the field of musculoskeletal imaging. The company has recently broadened its clinical studies evaluating the Accuro® XV system from two to eight clinical sites across the United States. This ambitious expansion aims to enhance the development of automated fracture detection algorithms derived from advanced volumetric ultrasound imaging.

As part of this effort, RIVANNA has secured funding from the Biomedical Advanced Research and Development Authority (BARDA), which operates under the U.S. Department of Health and Human Services (HHS). This funding is instrumental in advancing RIVANNA's research, positioning the company closer to groundbreaking developments in emergency medicine and fracture care.

Pioneering Fracture Detection Technology

The core of this study focuses on developing the very first automated fracture detection algorithm using volumetric ultrasound imaging, a pivotal moment in the evolution of diagnostic imaging. The study leverages RIVANNA's computer-aided detection (CADe/x) technology, which will utilize an expansive dataset of 3D images from upper and lower extremity injuries collected at the eight participating clinical sites. This innovative approach represents a remarkable leap in musculoskeletal imaging capabilities.

The clinical sites include prominent institutions such as Denver Health, Texas Tech Health El Paso, and the University of California, San Francisco, among others. Distinguished emergency physicians, with nearly a century of collective experience, are enthusiastic about participating in this transformative study that examines alternative imaging technologies to improve patient care in emergency settings.

Building a Robust Database

One of the primary goals of the expanded clinical study is to establish a comprehensive database of clinical images that will be crucial for training the CADe/x AI-enabled fracture detection algorithm and validating the BoneEnhance® module, which aims to improve bone visualization significantly. This initiative represents vital steps towards RIVANNA’s ambition of creating a comprehensive diagnostic platform for musculoskeletal injuries.

Dr. Delphine Le Roux, Senior Director at RIVANNA, has expressed optimism about the accelerated timeline for FDA 510(k) submission, now that all eight clinical sites are actively enrolling patients. The expanded program reflects the strong partnerships RIVANNA has developed with leading academic medical centers, which are essential to advancing this innovative technology.

Enhancements to Emergency Medicine

As noted by Dr. Christopher Thom, Associate Professor of Emergency Medicine at UVA, enhancing the Accuro XV system to highlight fractures represents a significant advancement in point-of-care imaging. This first-of-its-kind automated fracture detection system derived from volumetric imaging holds the potential to reshape the evaluation of extremity injuries at the bedside.

The study is additionally yielding important clinical insights. Preliminary analysis of patient cases has demonstrated that, among those who did not receive pain medication, the Accuro XV imaging system was associated with a notable reduction in pain compared to traditional X-ray imaging. These findings, which have yet to be published, suggest potential benefits to patient experience in conjunction with the diagnostic advantages of the Accuro XV.

About the Accuro XV System

The Accuro XV is a versatile, portable ultrasound imaging solution designed for musculoskeletal applications. Featuring a unique conformed three-dimensional probe, it facilitates large field-of-view image acquisition without exposing patients to ionizing radiation. With its AI-enhanced decision-support features approaching FDA clearance, the device will incorporate BoneEnhance software for improved visualization and CADe/x capabilities to assist clinicians in identifying fractures based on volumetric scans. This technology aims to enhance the initial assessment process in emergency departments, streamline workflows, and provide more efficient diagnosis of low-severity extremity injuries while reducing reliance on conventional X-ray referrals.

RIVANNA's commitment to improving musculoskeletal injury care is evident through its innovative approach and significant advancements in emergency preparedness. Supported by federal funding and backed by a portfolio of 100+ patents, RIVANNA continues to shape the future of healthcare technology, ensuring patients receive quality care with cutting-edge solutions.

Conclusion

RIVANNA's expansion of the Accuro XV clinical study marks a milestone not just for the company, but for the entire field of emergency medicine. With its commitment to enhancing diagnostics and patient care, RIVANNA is paving the way for a future where technology plays an integral role in delivering timely and effective healthcare solutions.